Showing 1351-1360 of 2656 results for "".
- Jay S. Duker, MD, Named President and CEO of Eyepoint Pharmaceuticalshttps://modernod.com/news/jay-s-duker-md-named-ceo-of-eyepoint-pharmaceuticals/2481715/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as President and Chief Executive Officer. Dr. Duker has transitioned from his most recent role as Chief Operating Officer (COO) and President. Dr. Duker has also been appointed to the Board of Di
- WHO Grants Emergency Listing to Sinovac’s Coronavirus Vaccinehttps://modernod.com/news/who-grants-emergency-listing-to-sinovacs-coronavirus-vaccine/2479253/The World Health Organization (WHO) issued an emergency-use listing for Sinovac’s inactivated COVID-19 vaccine CoronaVac in adults aged 18 and over, the second such authorization it has granted to a Chinese company, and the seventh listing overall, according to a FirstWord report. Sinopharm
- Sinopharm’s COVID-19 Vaccine Granted WHO Emergency Listinghttps://modernod.com/news/sinopharms-covid-19-vaccine-granted-who-emergency-listing/2479184/The World Health Organization (WHO) on Friday approved Sinopharm’s COVID-19 vaccine for emergency use, paving the way for millions more doses to be included into the COVAX program in the coming weeks or months for rollout in developing countries, according to a FirstWord report. The decisio
- FDA Approves Rayner’s RayOne EMV IOLhttps://modernod.com/news/fda-approves-rayners-rayone-emv-iol/2479019/Rayner’s RayOne EMV fully preloaded non-diffractive IOL has received FDA approval. RayOne EMV was developed in collaboration with renowned surgeon Professor Graham Barrett, president of the Australasian Society of Cataract & Refractive Surgeons. Dr. Mariano Royo, Director
- FDA Panel Endorses Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/fda-panel-endorses-pfizer-biontechs-covid-19-vaccine/2478650/An FDA advisory panel that convened Thursday to discuss Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 voted 17-4, with one abstention, in favor of authorizing it for emergency use in people 16 years and older. The vote follows the release of briefing documents earlier this week in which F
- Canada Authorises Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/canada-authorises-pfizer-biontechs-covid-19-vaccine/2478645/Health Canada announced that it has authorized Pfizer and BioNTech’s mRNA-based coronavirus vaccine BNT162b2 (tozinameran) under an interim order for emergency use, becoming the third country to do so after the UK and Bahrain. The initial indication of the vaccine in Canada is for use in pe
- Kerry Solomon First in US to Implant Alcon’s Vivity IOLhttps://modernod.com/news/kerry-solomon-first-in-nation-to-implant-alcons-vivity-iol/2478619/Kerry Solomon, MD, partner at Carolina Eyecare Physicians, Charleston, South Carolina, is the first in the United States following FDA approval to complete surgery using Alcon’s AcrySof IQ Vivity Extended Range of Vision IOL, according to a news release. “The Vivity lens is a remarka
- UK Authorizes Use of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/uk-authorizes-use-of-pfizer-biontechs-covid-19-vaccine/2478614/The UK government said Wednesday that it accepted a recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to grant temporary authorization of Pfizer and BioNTech’s mRNA-based COVID-19 vaccine BNT162b2. A Department of Health and Social Care spokesperson said 
- Optometry’s Meeting Cancelled Due to COVID-19https://modernod.com/news/optometrys-meeting-cancelled-due-to-covid-19/2477565/Out of an abundance of caution amid the ongoing COVID-19 pandemic, the American Optometric Association (AOA) has officially cancelled the annual Optometry’s Meeting, scheduled to take place on June 24-28 in Washington DC. The annual meeting of both the AOA and American Optometric Student As
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra